Mets News
Loaisiga Is the Mets' Kind of Gamble, but Only If Stearns Keeps the Contract Short
The Mets are reportedly serious about Jonathan Loaisiga. Here's why the stuff is real, why the injury history is a red flag, and what kind of deal makes sense.
The Mets' bullpen hunt just picked up a name Yankees fans know well., with the Phillies also heavily involved. A Monday report from amNewYork adds that the Yankees' interest is cooling, which leaves the Mets looking like the more serious suitor.
What makes this interesting is how much it cuts against the pattern. Of the six relievers the Mets have been tied to so far this winter, five are lefties. Loaisiga is the right-handed outlier, and he brings a different kind of appeal: a high-90s fastball, a heavy sinker and a changeup that hitters keep chasing. Baseball Savant has his chase rate at 35.9 percent, good for the 93rd percentile. David Stearns said at the GM Meetings that his bullpen priority is bringing in arms who can get hitters out. Missing bats is the clearest version of that.
The need is real. Devin Williams had a rough first season in Queens, the deadline sell-off sent Brooks Raley and A.J. Minter elsewhere, and the pen is heading into a rebuild. Stearns has pointed to Nate Lavender, Daniel Duarte and Dedniel Nunez as internal pieces, and Reed Garrett should be back at the start of 2027 after missing a full year. Lavender and Cionel Perez gave the team about 51 innings at a 3.00 ERA between them, which is a nice foundation. It's still a foundation, not a bullpen.
Then there is the part that makes every Mets fan wince: the medical file. Loaisiga has had two major elbow surgeries, a separate procedure to clear bone spurs, and trouble with his shoulder and a flexor tendon. 2026 was his first fully healthy season since 2021. One clean year is encouraging. It is not a track record, and the Mets have lived through enough pitching injuries lately to know the difference.
So here is where I land. If Loaisiga costs a short deal with performance bonuses, I'm in. The upside is a legitimate high-leverage arm, and the downside is a modest hit to the payroll. If it takes a multi-year commitment built on one healthy season, I'd walk away. Stearns' pattern backs that instinct: the three-year, $51 million Williams contract is the biggest he has ever given a reliever, and the Mets have mostly built their pen with cheaper, shorter bets. Loaisiga fits the bargain-bin-with-upside mold only if the structure stays that way.
The Phillies angle matters too. Every reliever who lands in Philadelphia is one the Mets have to face 13 times a year, and landing the same arm helps you twice. That alone is a reason to stay aggressive, as long as the price stays sane.
Keep an eye on three things from here. First, whether Loaisiga's physical and the length of the ask push the Mets toward a different target. Second, whether Stearns still adds a left-hander, whether that is a reunion with Minter or Raley or a free agent like JoJo Romero, because one righty does not solve the Lavender-and-Perez workload question. Third, how quickly the market moves. With the lockout clock ticking in the background, the best bullpen arms tend to come off the board fast.
The Mets don't need a hero in the ninth. They need a deeper, nastier middle of the bullpen, and Loaisiga could be part of that. Just keep the contract short and the expectations realistic.


